110
Participants
Start Date
May 31, 2006
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Sensipar (Cinacalcet HCl)
All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
Research Site, Skopje
Research Site, Brussels
Research Site, Budapest
Research Site, Antwerp
Research Site, Antwerp
Research Site, Leuven
Research Site, Miskolc
Research Site, Liège
Research Site, Debrecen
Research Site, Nyíregyháza
Research Site, Zurich
Research Site, Győr
Research Site, New York
Research Site, The Bronx
Research Site, Great Neck
Research Site, Flushing
Research Site, Genova
Research Site, Allentown
Research Site, Milan
Research Site, Baltimore
Research Site, Cremona
Research Site, Madrid
Research Site, Alcorcón
Research Site, Fort Lauderdale
Research Site, Izmir
Research Site, Santander
Research Site, Evanston
Research Site, St Louis
Research Site, Ortona CH
Research Site, New Orleans
Research Site, Houston
Research Site, Denver
Research Site, Avellino
Research Site, Phoenix
Research Site, Los Angeles
Research Site, New Haven
Research Site, Teaneck
Research Site, Hradec Králové
Research Site, Prague
Research Site, Ostia RM
Research Site, Roma
Research Site, Roma
Research Site, Roma (RM)
Research Site, Krakow
Research Site, Lodz
Research Site, Wroclaw
Research Site, Porto
Research Site, Almada
Research Site, Estoril
Research Site, Guimarães
Research Site, Porto
Research Site, Vila Franca de Xira
Research Site, Barcelona
Research Site, Barcelona
Research Site, Manchester
Lead Sponsor
Amgen
INDUSTRY